Peter Collins

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Disorders

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Luongo Cindy; Yang Lijuan; Winter Christine C; Spann Kirsten M; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
Zhang Liqun; Button Brian; Gabriel Sherif E; Burkett Susan; Yan Yu; Skiadopoulos Mario H; Dang Yan Li; Vogel Leatrice N; McKay Tristan; Mengos April; Boucher Richard C; Collins Peter L; Pickles Raymond J
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.
Moore Martin L; Chi Michael H; Luongo Cindy; Lukacs Nicholas W; Polosukhin Vasiliy V; Huckabee Matthew M; Newcomb Dawn C; Buchholz Ursula J; Crowe James E; Goleniewska Kasia; Williams John V; Collins Peter L; Peebles R Stokes
A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Peter Collins (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Luongo Cindy; Yang Lijuan; Winter Christine C; Spann Kirsten M; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
Vaccine 2009;27(41):5667-76.
2009: Zhang Liqun; Button Brian; Gabriel Sherif E; Burkett Susan; Yan Yu; Skiadopoulos Mario H; Dang Yan Li; Vogel Leatrice N; McKay Tristan; Mengos April; Boucher Richard C; Collins Peter L; Pickles Raymond J
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.
PLoS biology 2009;7(7):e1000155.
2009: Moore Martin L; Chi Michael H; Luongo Cindy; Lukacs Nicholas W; Polosukhin Vasiliy V; Huckabee Matthew M; Newcomb Dawn C; Buchholz Ursula J; Crowe James E; Goleniewska Kasia; Williams John V; Collins Peter L; Peebles R Stokes
A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.
Journal of virology 2009;83(9):4185-94.
2009: Dinapoli Joshua M; Ward Jerrold M; Cheng Lily; Yang Lijuan; Elankumaran Subbiah; Murphy Brian R; Samal Siba K; Collins Peter L; Bukreyev Alexander
Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.
Vaccine 2009;27(10):1530-9.
2009: Le Nouën Cyril; Munir Shirin; Losq Stéphanie; Winter Christine C; McCarty Thomas; Stephany David A; Holmes Kevin L; Bukreyev Alexander; Rabin Ronald L; Collins Peter L; Buchholz Ursula J
Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3.
Virology 2009;385(1):169-82.
2009: Buchholz Ursula J; Ward Jerrold M; Lamirande Elaine W; Heinze Britta; Krempl Christine D; Collins Peter L
Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease.
Journal of virology 2009;83(4):1969-80.
2009: Boonyaratanakornkit Jim B; Bartlett Emmalene J; Amaro-Carambot Emerito; Collins Peter L; Murphy Brian R; Schmidt Alexander C
The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.
Journal of virology 2009;83(4):1892-910.
2009: Bukreyev Alexander; Marzi Andrea; Feldmann Friederike; Zhang Liqun; Yang Lijuan; Ward Jerrold M; Dorward David W; Pickles Raymond J; Murphy Brian R; Feldmann Heinz; Collins Peter L
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
Virology 2009;383(2):348-61.
2008: Bukreyev Alexander; Yang Lijuan; Fricke Jens; Cheng Lily; Ward Jerrold M; Murphy Brian R; Collins Peter L
The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
Journal of virology 2008;82(24):12191-204.
2008: Bartlett Emmalene J; Cruz Ann-Marie; Esker Janice; Castaño Adam; Schomacker Henrick; Surman Sonja R; Hennessey Margaret; Boonyaratanakornkit Jim; Pickles Raymond J; Collins Peter L; Murphy Brian R; Schmidt Alexander C
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.
Journal of virology 2008;82(18):8965-77.
2008: Munir Shirin; Le Nouen Cyril; Luongo Cindy; Buchholz Ursula J; Collins Peter L; Bukreyev Alexander
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.
Journal of virology 2008;82(17):8780-96.
2008: Yang Lijuan; Sanchez Anthony; Ward Jerrold M; Murphy Brian R; Collins Peter L; Bukreyev Alexander
A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
Virology 2008;377(2):255-64.
2008: Bartlett Emmalene J; Hennessey Margaret; Skiadopoulos Mario H; Schmidt Alexander C; Collins Peter L; Murphy Brian R; Pickles Raymond J
Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.
Journal of virology 2008;82(16):8059-70.
2008: Collins Peter L; Graham Barney S
Viral and host factors in human respiratory syncytial virus pathogenesis.
Journal of virology 2008;82(5):2040-55.
2008: Bukreyev Alexander; Collins Peter L
Newcastle disease virus as a vaccine vector for humans.
Current opinion in molecular therapeutics 2008;10(1):46-55.
2008: DiNapoli Joshua M; Murphy Brian R; Collins Peter L; Bukreyev Alexander
Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection.
Virology journal 2008;5():105.
2007: Harker James; Bukreyev Alexander; Collins Peter L; Wang Belinda; Openshaw Peter J M; Tregoning John S
Virally delivered cytokines alter the immune response to future lung infections.
Journal of virology 2007;81(23):13105-11.
2007: DiNapoli Joshua M; Yang Lijuan; Suguitan Amorsolo; Elankumaran Subbiah; Dorward David W; Murphy Brian R; Samal Siba K; Collins Peter L; Bukreyev Alexander
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
Journal of virology 2007;81(21):11560-8.
2007: Wright Peter F; Karron Ruth A; Belshe Robert B; Shi Jian R; Randolph Valerie B; Collins Peter L; O'Shea Alice F; Gruber William C; Murphy Brian R
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Vaccine 2007;25(42):7372-8.
2007: Melendi Guillermina A; Zavala Fidel; Buchholz Ursula J; Boivin Guy; Collins Peter L; Kleeberger Steven R; Polack Fernando P
Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.
Journal of virology 2007;81(20):11461-7.
2007: Krempl Christine D; Wnekowicz Anna; Lamirande Elaine W; Nayebagha Giw; Collins Peter L; Buchholz Ursula J
Identification of a novel virulence factor in recombinant pneumonia virus of mice.
Journal of virology 2007;81(17):9490-501.
2007: Nolan Sheila M; Skiadopoulos Mario H; Bradley Konrad; Kim Olivia S; Bier Stacia; Amaro-Carambot Emerito; Surman Sonja R; Davis Stephanie; St Claire Marisa; Elkins Randy; Collins Peter L; Murphy Brian R; Schaap-Nutt Anne
Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
Vaccine 2007;25(34):6409-22.
2007: DiNapoli Joshua M; Kotelkin Alexander; Yang Lijuan; Elankumaran Subbiah; Murphy Brian R; Samal Siba K; Collins Peter L; Bukreyev Alexander
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(23):9788-93.
2007: Bukreyev Alexander; Rollin Pierre E; Tate Mallory K; Yang Lijuan; Zaki Sherif R; Shieh Wun-Ju; Murphy Brian R; Collins Peter L; Sanchez Anthony
Successful topical respiratory tract immunization of primates against Ebola virus.
Journal of virology 2007;81(12):6379-88.
2007: Biacchesi Stéphane; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro.
Journal of virology 2007;81(11):6057-67.
2007: Surman Sonja R; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.
Journal of virological methods 2007;141(1):30-3.
2007: Bartlett Emmalene J; Castaño Adam; Surman Sonja R; Collins Peter L; Skiadopoulos Mario H; Murphy Brian R
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
Virology journal 2007;4():67.
2006: Bukreyev Alexander; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L
Nonsegmented negative-strand viruses as vaccine vectors.
Journal of virology 2006;80(21):10293-306.
2006: Buchholz Ursula J; Nagashima Kunio; Murphy Brian R; Collins Peter L
Live vaccines for human metapneumovirus designed by reverse genetics.
Expert review of vaccines 2006;5(5):695-706.
2006: Van Cleve William; Amaro-Carambot Emerito; Surman Sonja R; Bekisz Joseph; Collins Peter L; Zoon Kathryn C; Murphy Brian R; Skiadopoulos Mario H; Bartlett Emmalene J
Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.
Virology 2006;352(1):61-73.
2006: Kotelkin Alexander; Belyakov Igor M; Yang Lijuan; Berzofsky Jay A; Collins Peter L; Bukreyev Alexander
The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.
Journal of virology 2006;80(12):5958-67.
2006: Bukreyev Alexander; Serra Maria Elina; Laham Federico R; Melendi Guillermina A; Kleeberger Steven R; Collins Peter L; Polack Fernando P
The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.
Journal of virology 2006;80(12):5854-61.
2006: Biacchesi Stéphane; Pham Quynh N; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates.
Journal of virology 2006;80(12):5798-806.
2006: Chi Bo; Dickensheets Harold L; Spann Kirsten M; Alston Marc A; Luongo Cindy; Dumoutier Laure; Huang Jiaying; Renauld Jean-Christophe; Kotenko Sergei V; Roederer Mario; Beeler Judy A; Donnelly Raymond P; Collins Peter L; Rabin Ronald L
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.
Journal of virology 2006;80(10):5032-40.
2006: Bukreyev Alexander; Yang Lijuan; Zaki Sherif R; Shieh Wun-Ju; Rollin Pierre E; Murphy Brian R; Collins Peter L; Sanchez Anthony
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Journal of virology 2006;80(5):2267-79.
2006: Bartlett Emmalene J; Amaro-Carambot Emerito; Surman Sonja R; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
Vaccine 2006;24(14):2674-84.
2006: Wright Peter F; Karron Ruth A; Madhi Shabir A; Treanor John J; King James C; O'Shea Alice; Ikizler Mine R; Zhu Yuwei; Collins Peter L; Cutland Clare; Randolph Valerie B; Deatly Anne M; Hackell Jill G; Gruber William C; Murphy Brian R
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.
The Journal of infectious diseases 2006;193(4):573-81.
2006: Skiadopoulos Mario H; Biacchesi Stéphane; Buchholz Ursula J; Amaro-Carambot Emérito; Surman Sonja R; Collins Peter L; Murphy Brian R
Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.
Virology 2006;345(2):492-501.
2005: Sims Amy C; Baric Ralph S; Yount Boyd; Burkett Susan E; Collins Peter L; Pickles Raymond J
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs.
Journal of virology 2005;79(24):15511-24.
2005: Pham Quynh N; Biacchesi Stéphane; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo.
Journal of virology 2005;79(24):15114-22.
2005: Bukreyev Alexander; Huang Zhuhui; Yang Lijuan; Elankumaran Subbiah; St Claire Marisa; Murphy Brian R; Samal Siba K; Collins Peter L
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Journal of virology 2005;79(21):13275-84.
2005: Biacchesi Stéphane; Pham Quynh N; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates.
Journal of virology 2005;79(19):12608-13.
2005: Tarran Robert; Button Brian; Picher Maryse; Paradiso Anthony M; Ribeiro Carla M; Lazarowski Eduardo R; Zhang Liqun; Collins Peter L; Pickles Raymond J; Fredberg Jeffrey J; Boucher Richard C
Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections.
The Journal of biological chemistry 2005;280(42):35751-9.
2005: Nolan Sheila M; Surman Sonja R; Amaro-Carambot Emerito; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
Vaccine 2005;23(39):4765-74.
2005: Biacchesi Stéphane; Skiadopoulos Mario H; Yang Lijuan; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression.
Journal of virological methods 2005;128(1-2):192-7.
2005: Bartlett Emmalene J; Amaro-Carambot Emerito; Surman Sonja R; Newman Jason T; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
Vaccine 2005;23(38):4631-46.
2005: Bukreyev Alexander; Belyakov Igor M; Prince Gregory A; Yim Kevin C; Harris Katie K; Berzofsky Jay A; Collins Peter L
Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
Journal of virology 2005;79(15):9515-26.
2005: Polack Fernando P; Irusta Pablo M; Hoffman Scott J; Schiatti M Paula; Melendi Guillermina A; Delgado M Florencia; Laham Federico R; Thumar Bhagvanji; Hendry R Michael; Melero Jose A; Karron Ruth A; Collins Peter L; Kleeberger Steven R
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(25):8996-9001.
2005: Buchholz Ursula J; Biacchesi Stéphane; Pham Quynh N; Tran Kim C; Yang Lijuan; Luongo Cindy L; Skiadopoulos Mario H; Murphy Brian R; Collins Peter L
Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity.
Journal of virology 2005;79(11):6588-97.
2005: Spann Kirsten M; Tran Kim C; Collins Peter L
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines.
Journal of virology 2005;79(9):5353-62.
2005: Gower Tara L; Pastey Manoj K; Peeples Mark E; Collins Peter L; McCurdy Lewis H; Hart Timothy K; Guth Alex; Johnson Teresa R; Graham Barney S
RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology.
Journal of virology 2005;79(9):5326-36.
2005: Karron Ruth A; Wright Peter F; Belshe Robert B; Thumar Bhagvanji; Casey Roberta; Newman Frances; Polack Fernando P; Randolph Valerie B; Deatly Anne; Hackell Jill; Gruber William; Murphy Brian R; Collins Peter L
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
The Journal of infectious diseases 2005;191(7):1093-104.
2005: Krempl Christine D; Lamirande Elaine W; Collins Peter L
Complete sequence of the RNA genome of pneumonia virus of mice (PVM).
Virus genes 2005;30(2):237-49.
2005: Zhang Liqun; Bukreyev Alexander; Thompson Catherine I; Watson Brandy; Peeples Mark E; Collins Peter L; Pickles Raymond J
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.
Journal of virology 2005;79(2):1113-24.
2005: Collins Peter L; Murphy Brian R
New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.
Proceedings of the American Thoracic Society 2005;2(2):166-73.
2004: Krempl Christine D; Collins Peter L
Reevaluation of the virulence of prototypic strain 15 of pneumonia virus of mice.
Journal of virology 2004;78(23):13362-5.
2004: Biacchesi Stéphane; Skiadopoulos Mario H; Yang Lijuan; Lamirande Elaine W; Tran Kim C; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.
Journal of virology 2004;78(23):12877-87.
2004: Skiadopoulos Mario H; Biacchesi Stéphane; Buchholz Ursula J; Riggs Jeffrey M; Surman Sonja R; Amaro-Carambot Emerito; McAuliffe Josephine M; Elkins William R; St Claire Marisa; Collins Peter L; Murphy Brian R
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.
Journal of virology 2004;78(13):6927-37.
2004: Bukreyev Alexander; Lamirande Elaine W; Buchholz Ursula J; Vogel Leatrice N; Elkins William R; St Claire Marisa; Murphy Brian R; Subbarao Kanta; Collins Peter L
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Lancet 2004;363(9427):2122-7.
2004: Buchholz Ursula J; Bukreyev Alexander; Yang Lijuan; Lamirande Elaine W; Murphy Brian R; Subbarao Kanta; Collins Peter L
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(26):9804-9.
2004: Bisht Himani; Roberts Anjeanette; Vogel Leatrice; Bukreyev Alexander; Collins Peter L; Murphy Brian R; Subbarao Kanta; Moss Bernard
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(17):6641-6.
2004: Biacchesi Stéphane; Skiadopoulos Mario H; Tran Kim C; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes.
Virology 2004;321(2):247-59.
2004: Spann Kirsten M; Tran Kim-C; Chi Bo; Rabin Ronald L; Collins Peter L
Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected].
Journal of virology 2004;78(8):4363-9.
2004: McAuliffe Josephine M; Surman Sonja R; Newman Jason T; Riggs Jeffrey M; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
Journal of virology 2004;78(4):2029-36.
2004: Newman Jason T; Riggs Jeffrey M; Surman Sonja R; McAuliffe Josephine M; Mulaikal Teresa A; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Journal of virology 2004;78(4):2017-28.
2004: Tran Kim C; Collins Peter L; Teng Michael N
Effects of altering the transcription termination signals of respiratory syncytial virus on viral gene expression and growth in vitro and in vivo.
Journal of virology 2004;78(2):692-9.
2003: Biacchesi Stéphane; Skiadopoulos Mario H; Boivin Guy; Hanson Christopher T; Murphy Brian R; Collins Peter L; Buchholz Ursula J
Genetic diversity between human metapneumovirus subgroups.
Virology 2003;315(1):1-9.
2003: Spann Kirsten M; Collins Peter L; Teng Michael N
Genetic recombination during coinfection of two mutants of human respiratory syncytial virus.
Journal of virology 2003;77(20):11201-11.
2003: Kotelkin Alexander; Prikhod'ko Elena A; Cohen Jeffrey I; Collins Peter L; Bukreyev Alexander
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.
Journal of virology 2003;77(17):9156-72.
2003: Skiadopoulos Mario H; Schmidt Alexander C; Riggs Jeffrey M; Surman Sonja R; Elkins William R; St Claire Marisa; Collins Peter L; Murphy Brian R
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
Journal of virology 2003;77(2):1141-8.
2003: Skiadopoulos Mario H; Vogel Leatrice; Riggs Jeffrey M; Surman Sonja R; Collins Peter L; Murphy Brian R
The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.
Journal of virology 2003;77(1):270-9.
2002: Bukreyev Alexander; Skiadopoulos Mario H; McAuliffe Josephine; Murphy Brian R; Collins Peter L; Schmidt Alexander C
More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?
Proceedings of the National Academy of Sciences of the United States of America 2002;99(26):16987-91.
2002: Krempl Christine; Murphy Brian R; Collins Peter L
Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.
Journal of virology 2002;76(23):11931-42.
2002: Polack Fernando P; Teng Michael N; Collins Peter L; Prince Gregory A; Exner Marcus; Regele Heinz; Lirman Dario D; Rabold Richard; Hoffman Scott J; Karp Christopher L; Kleeberger Steven R; Wills-Karp Marsha; Karron Ruth A
A role for immune complexes in enhanced respiratory syncytial virus disease.
The Journal of experimental medicine 2002;196(6):859-65.
2002: Murphy Brian R; Collins Peter L
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.
The Journal of clinical investigation 2002;110(1):21-7.
2002: Teng Michael N; Collins Peter L
The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.
Journal of virology 2002;76(12):6164-71.
2002: Zhang Liqun; Peeples Mark E; Boucher Richard C; Collins Peter L; Pickles Raymond J
Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.
Journal of virology 2002;76(11):5654-66.
2002: Skiadopoulos Mario H; Surman Sonja R; Riggs Jeffrey M; Elkins William R; St Claire Marisa; Nishio Machiko; Garcin Dominique; Kolakofsky Daniel; Collins Peter L; Murphy Brian R
Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.
Virology 2002;297(1):153-60.
2002: Skiadopoulos Mario H; Surman Sonja R; Riggs Jeffrey M; Orvell Claes; Collins Peter L; Murphy Brian R
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Virology 2002;297(1):136-52.
2002: Collins Peter L; Murphy Brian R
Respiratory syncytial virus: reverse genetics and vaccine strategies.
Virology 2002;296(2):204-11.
2002: Techaarpornkul Sunee; Collins Peter L; Peeples Mark E
Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.
Virology 2002;294(2):296-304.
2002: Fearns Rachel; Peeples Mark E; Collins Peter L
Mapping the transcription and replication promoters of respiratory syncytial virus.
Journal of virology 2002;76(4):1663-72.
2002: Schmidt Alexander C; Wenzke Daniel R; McAuliffe Josephine M; St Claire Marisa; Elkins William R; Murphy Brian R; Collins Peter L
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Journal of virology 2002;76(3):1089-99.
2002: Newman Jason T; Surman Sonja R; Riggs Jeffrey M; Hansen Chris T; Collins Peter L; Murphy Brian R; Skiadopoulos Mario H
Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.
Virus genes 2002;24(1):77-92.
2001: Bukreyev A; Belyakov I M; Berzofsky J A; Murphy B R; Collins P L
Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.
Journal of virology 2001;75(24):12128-40.
2001: Skiadopoulos M H; Surman S R; Riggs J M; Collins P L; Murphy B R
A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Journal of virology 2001;75(21):10498-504.
2001: Teng M N; Whitehead S S; Collins P L
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.
Virology 2001;289(2):283-96.
2001: Sutherland K A; Collins P L; Peeples M E
Synergistic effects of gene-end signal mutations and the M2-1 protein on transcription termination by respiratory syncytial virus.
Virology 2001;288(2):295-307.
2001: Tao T; Skiadopoulos M H; Davoodi F; Surman S R; Collins P L; Murphy B R
Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
Vaccine 2001;19(27):3620-31.
2001: Gower T L; Peeples M E; Collins P L; Graham B S
RhoA is activated during respiratory syncytial virus infection.
Virology 2001;283(2):188-96.
2001: Schmidt A C; McAuliffe J M; Murphy B R; Collins P L
Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Journal of virology 2001;75(10):4594-603.
2000: Bukreyev A; Murphy B R; Collins P L
Respiratory syncytial virus can tolerate an intergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo.
Journal of virology 2000;74(23):11017-26.
2000: Hallak L K; Spillmann D; Collins P L; Peeples M E
Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.
Journal of virology 2000;74(22):10508-13.
2000: Teng M N; Whitehead S S; Bermingham A; St Claire M; Elkins W R; Murphy B R; Collins P L
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.
Journal of virology 2000;74(19):9317-21.
2000: Schmidt A C; McAuliffe J M; Huang A; Surman S R; Bailly J E; Elkins W R; Collins P L; Murphy B R; Skiadopoulos M H
Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Journal of virology 2000;74(19):8922-9.
2000: Bukreyev A; Whitehead S S; Prussin C; Murphy B R; Collins P L
Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines.
Journal of virology 2000;74(15):7151-7.
2000: Durbin A P; Skiadopoulos M H; McAuliffe J M; Riggs J M; Surman S R; Collins P L; Murphy B R
Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Journal of virology 2000;74(15):6821-31.
2000: Tao T; Skiadopoulos M H; Davoodi F; Riggs J M; Collins P L; Murphy B R
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Journal of virology 2000;74(14):6448-58.
2000: Fearns R; Collins P L; Peeples M E
Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus.
Journal of virology 2000;74(13):6006-14.
2000: Skiadopoulos M H; Surman S R; Durbin A P; Collins P L; Murphy B R
Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
Virology 2000;272(1):225-34.
2000: Hallak L K; Collins P L; Knudson W; Peeples M E
Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.
Virology 2000;271(2):264-75.
2000: Bailly J E; McAuliffe J M; Durbin A P; Elkins W R; Collins P L; Murphy B R
A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
Journal of virology 2000;74(7):3188-95.
2000: Buchholz U J; Granzow H; Schuldt K; Whitehead S S; Murphy B R; Collins P L
Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
Journal of virology 2000;74(3):1187-99.
2000: Tao T; Davoodi F; Cho C J; Skiadopoulos M H; Durbin A P; Collins P L; Murphy B R
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Vaccine 2000;18(14):1359-66.
2000: Peeples M E; Collins P L
Mutations in the 5' trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step.
Journal of virology 2000;74(1):146-55.
2000: Bailly J E; McAuliffe J M; Skiadopoulos M H; Collins P L; Murphy B R
Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.
Virus genes 2000;20(2):173-82.
1999: Whitehead S S; Hill M G; Firestone C Y; St Claire M; Elkins W R; Murphy B R; Collins P L
Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
Journal of virology 1999;73(12):9773-80.
1999: Skiadopoulos M H; Tao T; Surman S R; Collins P L; Murphy B R
Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
Vaccine 1999;18(5-6):503-10.
1999: Bermingham A; Collins P L
The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(20):11259-64.
1999: Durbin A P; McAuliffe J M; Collins P L; Murphy B R
Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.
Virology 1999;261(2):319-30.
1999: Skiadopoulos M H; Surman S R; St Claire M; Elkins W R; Collins P L; Murphy B R
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Virology 1999;260(1):125-35.
1999: Collins P L; Camargo E; Hill M G
Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus.
Virology 1999;259(2):251-5.
1999: Fearns R; Collins P L
Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription.
Journal of virology 1999;73(7):5852-64.
1999: Juhasz K; Murphy B R; Collins P L
The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.
Journal of virology 1999;73(6):5176-80.
1999: Whitehead S S; Bukreyev A; Teng M N; Firestone C Y; St Claire M; Elkins W R; Collins P L; Murphy B R
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
Journal of virology 1999;73(4):3438-42.
1999: Juhasz K; Whitehead S S; Boulanger C A; Firestone C Y; Collins P L; Murphy B R
The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.
Vaccine 1999;17(11-12):1416-24.
1999: Tao T; Skiadopoulos M H; Durbin A P; Davoodi F; Collins P L; Murphy B R
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Vaccine 1999;17(9-10):1100-8.
1999: Bukreyev A; Whitehead S S; Bukreyeva N; Murphy B R; Collins P L
Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2367-72.
1999: Skiadopoulos M H; Surman S; Tatem J M; Paschalis M; Wu S L; Udem S A; Durbin A P; Collins P L; Murphy B R
Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
Journal of virology 1999;73(2):1374-81.
1999: Whitehead S S; Firestone C Y; Karron R A; Crowe J E; Elkins W R; Collins P L; Murphy B R
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
Journal of virology 1999;73(2):871-7.
1999: Teng M N; Collins P L
Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein.
Journal of virology 1999;73(1):466-73.
1999: Fearns R; Collins P L
Model for polymerase access to the overlapped L gene of respiratory syncytial virus.
Journal of virology 1999;73(1):388-97.
1999: Collins P L; Whitehead S S; Bukreyev A; Fearns R; Teng M N; Juhasz K; Chanock R M; Murphy B R
Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.
Advances in virus research 1999;54():423-51.
1998: Whitehead S S; Firestone C Y; Collins P L; Murphy B R
A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
Virology 1998;247(2):232-9.
1998: Teng M N; Collins P L
Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles.
Journal of virology 1998;72(7):5707-16.
1998: Whitehead S S; Juhasz K; Firestone C Y; Collins P L; Murphy B R
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.
Journal of virology 1998;72(5):4467-71.
1998: Tao T; Durbin A P; Whitehead S S; Davoodi F; Collins P L; Murphy B R
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Journal of virology 1998;72(4):2955-61.
1998: Skiadopoulos M H; Durbin A P; Tatem J M; Wu S L; Paschalis M; Tao T; Collins P L; Murphy B R
Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
Journal of virology 1998;72(3):1762-8.
1998: Atreya P L; Peeples M E; Collins P L
The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication.
Journal of virology 1998;72(2):1452-61.
1997: Bukreyev A; Whitehead S S; Murphy B R; Collins P L
Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.
Journal of virology 1997;71(12):8973-82.
1997: Fearns R; Peeples M E; Collins P L
Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome.
Virology 1997;236(1):188-201.
1997: Durbin A P; Hall S L; Siew J W; Whitehead S S; Collins P L; Murphy B R
Recovery of infectious human parainfluenza virus type 3 from cDNA.
Virology 1997;235(2):323-32.
1997: Juhasz K; Whitehead S S; Bui P T; Biggs J M; Crowe J E; Boulanger C A; Collins P L; Murphy B R
The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.
Journal of virology 1997;71(8):5814-9.
1997: Durbin A P; Siew J W; Murphy B R; Collins P L
Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six.
Virology 1997;234(1):74-83.
1997: Kuo L; Fearns R; Collins P L
Analysis of the gene start and gene end signals of human respiratory syncytial virus: quasi-templated initiation at position 1 of the encoded mRNA.
Journal of virology 1997;71(7):4944-53.
1997: Murphy B R; Collins P L
Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
Bulletin of the World Health Organization 1997;75(4):307-13.
1996: Firestone C Y; Whitehead S S; Collins P L; Murphy B R; Crowe J E
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
Virology 1996;225(2):419-22.
1996: Kuo L; Grosfeld H; Cristina J; Hill M G; Collins P L
Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus.
Journal of virology 1996;70(10):6892-901.
1996: Bukreyev A; Camargo E; Collins P L
Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene.
Journal of virology 1996;70(10):6634-41.
1996: Kuo L; Fearns R; Collins P L
The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome.
Journal of virology 1996;70(9):6143-50.
1996: Collins P L; Hill M G; Cristina J; Grosfeld H
Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(1):81-5.
1996: Crowe J E; Firestone C Y; Whitehead S S; Collins P L; Murphy B R
Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.
Virus genes 1996;13(3):269-73.
1995: Collins P L; Hill M G; Camargo E; Grosfeld H; Chanock R M; Murphy B R
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11563-7.
1995: Grosfeld H; Hill M G; Collins P L
RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.
Journal of virology 1995;69(9):5677-86.
1995: Connors M; Crowe J E; Firestone C Y; Murphy B R; Collins P L
A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.
Virology 1995;208(2):478-84.
1995: Kulkarni A B; Collins P L; Bacik I; Yewdell J W; Bennink J R; Crowe J E; Murphy B R
Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.
Journal of virology 1995;69(2):1261-4.
1994: Murphy B R; Hall S L; Kulkarni A B; Crowe J E; Collins P L; Connors M; Karron R A; Chanock R M
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
Virus research 1994;32(1):13-36.
1993: Crowe J E; Collins P L; London W T; Chanock R M; Murphy B R
A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
Vaccine 1993;11(14):1395-404.
1993: Collins P L; Mottet G
Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus.
The Journal of general virology 1993;74 ( Pt 7)():1445-50.
1993: Collins P L; Mink M A; Hill M G; Camargo E; Grosfeld H; Stec D S
Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA.
Virology 1993;195(1):252-6.
1993: Dimock K; Collins P L
Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3.
Journal of virology 1993;67(5):2772-8.
1993: Martin-Gallardo A; Fleischer E; Doyle S A; Arumugham R; Collins P L; Hildreth S W; Paradiso P R
Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.
The Journal of general virology 1993;74 ( Pt 3)():453-8.
1992: Chanock R M; Parrott R H; Connors M; Collins P L; Murphy B R
Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.
Pediatrics 1992;90(1 Pt 2):137-43.
1992: Gorziglia M I; Collins P L
Intracellular amplification and expression of a synthetic analog of rotavirus genomic RNA bearing a foreign marker gene: mapping cis-acting nucleotides in the 3'-noncoding region.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(13):5784-8.
1992: Collins P L; Mottet G
Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A.
The Journal of general virology 1992;73 ( Pt 4)():849-63.
1992: Connors M; Kulkarni A B; Collins P L; Firestone C Y; Holmes K L; Morse H C; Murphy B R
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
Journal of virology 1992;66(2):1277-81.
1992: Connors M; Collins P L; Firestone C Y; Sotnikov A V; Waitze A; Davis A R; Hung P P; Chanock R M; Murphy B R
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Vaccine 1992;10(7):475-84.
1991: Mink M A; Stec D S; Collins P L
Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA.
Virology 1991;185(2):615-24.
1991: Collins P L; Mottet G
Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.
The Journal of general virology 1991;72 ( Pt 12)():3095-101.
1991: Collins P L; Mink M A; Stec D S
Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(21):9663-7.
1991: Martin-Gallardo A; Fien K A; Hu B T; Farley J F; Seid R; Collins P L; Hildreth S W; Paradiso P R
Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope.
Virology 1991;184(1):428-32.
1991: Stec D S; Hill M G; Collins P L
Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses.
Virology 1991;183(1):273-87.
1991: Collins P L; Mottet G
Homooligomerization of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 occurs before the acquisition of correct intramolecular disulfide bonds and mature immunoreactivity.
Journal of virology 1991;65(5):2362-71.
1991: Murphy B R; Prince G A; Collins P L; Hildreth S W; Paradiso P R
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
Vaccine 1991;9(3):185-9.
1991: Connors M; Collins P L; Firestone C Y; Murphy B R
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
Journal of virology 1991;65(3):1634-7.
1990: Collins P L; Hill M G; Johnson P R
The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro.
The Journal of general virology 1990;71 ( Pt 12)():3015-20.
1990: Collins P L
O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.
Journal of virology 1990;64(8):4007-12.
1990: Collins P L; Olmsted R A; Johnson P R
The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B.
The Journal of general virology 1990;71 ( Pt 7)():1571-6.
1990: Spriggs M K; Collins P L
Intracellular processing and transport of NH2-terminally truncated forms of a hemagglutinin-neuraminidase type II glycoprotein.
The Journal of cell biology 1990;111(1):31-44.
1990: Murphy B R; Prince G A; Lawrence L A; Croen K D; Collins P L
Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.
Virus research 1990;16(2):153-62.
1990: Collins P L; Purcell R H; London W T; Lawrence L A; Chanock R M; Murphy B R
Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
Vaccine 1990;8(2):164-8.
1990: Johnson P R; Collins P L
Sequence comparison of the phosphoprotein mRNAs of antigenic subgroups A and B of human respiratory syncytial virus identifies a highly divergent domain in the predicted protein.
The Journal of general virology 1990;71 ( Pt 2)():481-5.
1989: Murphy B R; Collins P L; Lawrence L; Zubak J; Chanock R M; Prince G A
Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
The Journal of general virology 1989;70 ( Pt 8)():2185-90.
1989: Johnson P R; Collins P L
The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA.
The Journal of general virology 1989;70 ( Pt 6)():1539-47.
1989: Olmsted R A; Collins P L
The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species.
Journal of virology 1989;63(5):2019-29.
1989: Olmsted R A; Murphy B R; Lawrence L A; Elango N; Moss B; Collins P L
Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus.
Journal of virology 1989;63(1):411-20.
1988: Olmsted R A; Buller R M; Collins P L; London W T; Beeler J A; Prince G A; Chanock R M; Murphy B R
Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
Vaccine 1988;6(6):519-24.
1988: Johnson P R; Collins P L
The A and B subgroups of human respiratory syncytial virus: comparison of intergenic and gene-overlap sequences.
The Journal of general virology 1988;69 ( Pt 11)():2901-6.
1988: Johnson P R; Collins P L
The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness.
The Journal of general virology 1988;69 ( Pt 10)():2623-8.
1988: Murphy B R; Olmsted R A; Collins P L; Chanock R M; Prince G A
Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
Journal of virology 1988;62(10):3907-10.
1988: Murphy B R; Prince G A; Collins P L; Van Wyke Coelingh K; Olmsted R A; Spriggs M K; Parrott R H; Kim H W; Brandt C D; Chanock R M
Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
Virus research 1988;11(1):1-15.
1988: Chanock R M; Murphy B R; Collins P L; Coelingh K V; Olmsted R A; Snyder M H; Spriggs M K; Prince G A; Moss B; Flores J
Live viral vaccines for respiratory and enteric tract diseases.
Vaccine 1988;6(2):129-33.
1988: Spriggs M K; Collins P L; Tierney E; London W T; Murphy B R
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Journal of virology 1988;62(4):1293-6.
1987: Spriggs M K; Murphy B R; Prince G A; Olmsted R A; Collins P L
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Journal of virology 1987;61(11):3416-23.
1987: Johnson P R; Olmsted R A; Prince G A; Murphy B R; Alling D W; Walsh E E; Collins P L
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
Journal of virology 1987;61(10):3163-6.
1987: van Wyke Coelingh K L; Murphy B R; Collins P L; Lebacq-Verheyden A M; Battey J F
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.
Virology 1987;160(2):465-72.
1987: Johnson P R; Spriggs M K; Olmsted R A; Collins P L
The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(16):5625-9.
1987: Collins P L; Olmsted R A; Spriggs M K; Johnson P R; Buckler-White A J
Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(15):5134-8.
1986: Olmsted R A; Elango N; Prince G A; Murphy B R; Johnson P R; Moss B; Chanock R M; Collins P L
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(19):7462-6.
1986: Collins P L; Dickens L E; Buckler-White A; Olmsted R A; Spriggs M K; Camargo E; Coelingh K V
Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(13):4594-8.
1986: Spriggs M K; Olmsted R A; Venkatesan S; Coligan J E; Collins P L
Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses.
Virology 1986;152(1):241-51.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Peter Collins

Research Profile (preview)

Living Beings

Chemicals & Drugs

Physiology

Anatomy

Concepts & Ideas

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Peter Collins (preview)

All Publications